Warning: This security is no longer trading.
Ipsen completes acquisition of Clementia Pharma
Clementia Pharmaceuticals Inc. (CMTA): Price and Financial Metrics
CMTA Price/Volume Stats
| Current price | $26.35 | 52-week high | $26.73 |
| Prev. close | $26.38 | 52-week low | $8.10 |
| Day low | $26.28 | Volume | 716,700 |
| Day high | $26.69 | Avg. volume | 204,154 |
| 50-day MA | $23.18 | Dividend yield | N/A |
| 200-day MA | $14.63 | Market Cap | 1.00B |
CMTA Stock Price Chart Interactive Chart >
Clementia Pharmaceuticals Inc. (CMTA) Company Bio
Clementia Pharmaceuticals Inc., a clinical stage biopharmaceutical company, develops disease-modifying treatments for patients suffering from debilitating bone and other diseases. Its lead product candidate is palovarotene, an oral small molecule that binds and activates retinoic acid receptor gamma, and prevents abnormal new bone formation, as well as scar tissue formation in various tissues in animal models. The company is developing palovarotene for the treatment of fibrodysplasia ossificans progressiva and multiple osteochondroma, as well as has one Phase III and Phase II/III trials for two separate indications. Clementia Pharmaceuticals Inc. was founded in 2010 and is based in Montreal, Canada.
CMTA Price Returns
| 1-mo | N/A |
| 3-mo | N/A |
| 6-mo | N/A |
| 1-year | N/A |
| 3-year | N/A |
| 5-year | N/A |
| YTD | N/A |
| 2023 | N/A |
| 2022 | N/A |
| 2021 | N/A |
| 2020 | N/A |
| 2019 | N/A |
Loading social stream, please wait...